Previous 10 | Next 10 |
home / stock / hltrf / hltrf news
HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021 Canada NewsWire ...
HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call Canada NewsWire TORONTO , March 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by pre...
HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021 Canada NewsWire TORONTO , Feb. 23, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervo...
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021 Canada NewsWire TORONTO , Feb. 16, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and ...
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa® Canada NewsWire Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021 , up from 50% in November ...
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events Canada NewsWire Vascepa included in Consensus Statement by the American Association of Clinical...
HLS Therapeutics Announces Final Redemption of Preferred Shares Canada NewsWire - Redemption completes last step resulting from the 2018 Plan of Arrangement TORONTO , Jan. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS),...
HLS Therapeutics Announces Board Appointment Canada NewsWire TORONTO , Dec. 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces tha...
HLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs ...
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl) Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 C...
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc Company Name:
HLTRF Stock Symbol:
OTCMKTS Market:
HLS Therapeutics Announces First Quarter Fiscal 2021 Financial Results Canada NewsWire Q1 2021 revenue of $14.3 million , Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million , up $0.4 million , $0.6 million and $1.8 million ...
HLS Therapeutics to Host Q1 2021 Financial Results Conference Call Canada NewsWire TORONTO , April 22, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021 ...
HLS Therapeutics Announces Participation in Upcoming Conferences Canada NewsWire TORONTO , April 15, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular ma...